News & Updates
Filter by Specialty:
Pyrotinib + capecitabine extends OS in metastatic breast cancer
Patients with previously treated HER2-positive metastatic breast cancer (mBC) experienced a 31 percent reduced risk of death when treated with pyrotinib plus capecitabine than lapatinib plus capecitabine, according to updated results of the phase III PHOEBE trial from China.
Pyrotinib + capecitabine extends OS in metastatic breast cancer
10 Jan 2022
Prepregnancy adhrence to plant-based diets lowers risk of gestational diabetes mellitus
Women with greater adherence to a healthful plant-based diet before pregnancy appear to have a reduced risk of gestational diabetes mellitus (GDM), suggests a recent study. On the other hand, adherence to an unhealthful plant-based diet is not associated with GDM risk.
Prepregnancy adhrence to plant-based diets lowers risk of gestational diabetes mellitus
05 Jan 2022
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
In women with hormone-receptor positive advanced breast cancer (HR+ aBC), the addition of the class I selective histone deacetylase (HDAC) inhibitor entinostat to exemestane appeared to be better than treatment with exemestane alone in terms of survival benefit, according to a phase III trial from China.
Entinostat-exemestane combo yields survival benefit for HR+ advanced BC
04 Jan 2022
Novel SERD shows promise for ER+/HER2– advanced/metastatic breast cancer
The novel oral SERD* elacestrant demonstrated potential as new treatment alternative for ER+/HER2– advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy, according to the phase III EMERALD trial.
